HCT116-Luc Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | HCT 116-Luc is a luciferase-expressing derivative of the human colorectal carcinoma cell line HCT 116. The line was generated by transduction with a construct encoding firefly luciferase from Photinus pyralis together with a puromycin resistance cassette (pac), so reporter expression is constitutive rather than pathway-dependent. Bioluminescent signal is therefore proportional to viable cell number, which makes the model suitable for non-invasive tracking of tumour burden in vivo and for rapid, plate-based quantification of cell viability and proliferation in vitro. The parental HCT 116 line retains its defining features in this derivative, including microsatellite instability with deficient DNA mismatch repair, wild-type TP53, and a near-diploid karyotype. Its mutational background comprises KRAS p.Gly13Asp, PIK3CA p.His1047Arg, a heterozygous CTNNB1 p.Ser45del that stabilises β-catenin and drives constitutive Wnt signalling, and homozygous frameshift mutations in TGFBR2 and ACVR2A typical of MSI colorectal tumours. Additional variants are present in CDKN2A, EP300, BRCA2 and PPM1D. Stable integration of the reporter allows longitudinal imaging of orthotopic and subcutaneous xenografts in the same animal, reducing cohort sizes and removing the need for terminal endpoints at each time point. Puromycin selection is used to maintain the transgene during routine expansion. This line is widely applied in preclinical oncology, in efficacy studies of cytotoxic and targeted agents, in metastasis and tumour homing models, and in high-throughput cytotoxicity screening where a luminescent readout offers a wider dynamic range than colorimetric assays. Because luciferase expression is not under inducible control, the signal reports cell number and metabolic state rather than the activity of a specific pathway, so compounds that alter ATP levels or cellular metabolism can affect luminescence independently of cell killing. Orthogonal viability assays are recommended for confirmation, and the mismatch repair deficient background of HCT 116 should be considered when interpreting responses to DNA damaging agents and immunomodulatory treatments. |
|---|---|
| Organism | Human |
| Tissue | Colon |
| Disease | Colon carcinoma |
Characteristics
| Age | 48 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | HCT116-Luc (Cytion catalog number 305787) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_C8WT |
| GMO Status | GMO-S1: This cell line contains a stably integrated firefly luciferase reporter cassette (Luc2, codon-optimized) introduced via replication-incompetent lentiviral transduction. The resulting polyclonal cell population was maintained under puromycin selection (1–5 µg/mL). S1 containment is required. This classification applies only within Germany and may differ elsewhere. |
Biomolecular Data
| Antigen expression | Luc2 (firefly, codon-optimized) |
|---|---|
| Mutational profile | Mutation: p.Lys437Argfs*5, Homozygous; Mutation: p.Ile2675Aspfs*6, Heterozygous; Mutation: p.Arg24Serfs*20, Heterozygous; Mutation: p.Ser45del, Heterozygous; Mutation: p.Met1470Cysfs*22, Heterozygous; Mutation: p.Asn1700Thrfs*9, Heterozygous; Mutation: p.Gly13Asp, Heterozygous; Mutation: p.His1047Arg, Heterozygous; Mutation: p.Leu450Ter, Heterozygous; Mutation: p.Lys128Serfs*35, Homozygous |
Handling
| Culture Medium | McCoys 5a, w: 3.0 g/L Glucose, w: stable Glutamine, w: 2.0 mM Sodium pyruvate, w: 2.2 g/L NaHCO3 (Cytion article number 820200a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Seeding density | 1-3*10^4/cm² |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
| Product variants: | suspension |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305787-080526 | Certificate of Analysis | 24. Jun. 2026 | 305787 |
| 305787-080526 | Certificate of Analysis | 23. Sep. 2026 | 305787 |